// App-Quantinova.ai

SAT-0987 : Linagliptin Monotherapy Versus Initial Combination Therapy with Metformin in Patients with Newly Diagnosed Type 2 Diabetes (T2D): A Randomized Controlled Trial

Researchers

Presenter

  • Maximilian von Eynatten

Principal Investigators

  • Stuart Ross

  • Enrique Caballero

  • Stefano Del Prato

  • Baptist Gallwitz

  • Diane Lewis-D'Agostino

  • Zelie Bailes

  • Sandra Thiemann

  • Sanjay Patel

  • Hans-Juergen Woerle

Medical Centers

  • Boehringer-Ingelheim, Ridgefield, CT

  • Joslin Diabetes Ctr, Boston, MA

  • University of Pavia, Pavia, Italy

  • Universitts-Frauenklinik Tubingen, Tubingen, Germany

Locations

  • United States

  • Canada

  • Germany

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

Disease

  • Type 2 diabetes mellitus

  • Hyperglycemia

  • Diabetes

Biomarkers

  • Hemoglobin A1c

  • Body mass index

Drug/Treatment

  • Linagliptin

  • Metformin Hydrochloride

Outcome

  • N/A

Study Design

  • randomized

  • superiority

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved